U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid [Reuters (UK)]
CELGENE (CELG)
Last celgene earnings: 10/31 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celgene.com
Company Research
Source: Reuters
U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid | Reuters 1 Min Read (Reuters) - A U.S. administrative court on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp’s blockbuster myeloma drug Revlimid. The Patent Trial and Appeal Board, a court run by the U.S. patent office, said it was denying Alvogen’s petition for an inter-partes review on the patents of the drug. Drugmaker Bristol-Myers Squibb Co in January said it would buy Celgene Corporation for about $74 billion, to expand its pipeline of cancer drugs. Revlimid, Celgene’s cancer drug that brought in sales of $2.55 billion in the fourth quarter, faces loss of exclusivity beginning 2022 in the United States. Reporting by Manas Mishra in Bengaluru; Editing by James Emmanuel All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2019 Reuters. All Rights Reserved.
Show less
Read more
Impact Snapshot
Event Time:
CELG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELG alerts
High impacting CELGENE news events
Weekly update
A roundup of the hottest topics